POZ news story
HIV can develop capsid mutations that confer resistance to lenacapavir, but doing so can come at a cost to viral fitness, according to a study results published in Science Translational Medicine. These findings have implications for lenacapavir use for HIV treatment and pre-exposure prophylaxis (PrEP).
“As [lenacapavir] moves into broader use for both PrEP and treatment, these findings highlight the importance of maintaining fully active companion drugs during HIV treatment, improving access to resistance testing and surveillance, and accelerating development of next-generation capsid inhibitors,” Manish Choudhary, PhD, and Jonathan Li, MD, of Brigham and Women’s Hospital and Harvard Medical School, wrote in an accompanying commentary.
Read the full news story here.
